Catapult Life Science will contribute to activity and value creation in Norway, by providing facilities and expertise for research based product development.
Catapult Life Science is a centre where small and large players can find equipment, space, infrastructure and expertise, so they can develop their products in Norway. We are based at Fornebu, to be near the leading Norwegian life science environments, including the University of Oslo and Oslo University Hospital. We realise the importance of proximity for a centre that will enable the first steps towards industrialisation for startup companies arising from this environment. In parallel, we are working for the establishment of a future Catapult Centre for Life Sciences in the Ullevål-Gaustadbekkdalen area, in connection with the relocation of the major knowledge institutions related to the coming Life Science building.
We are bringing industry expertise in product development, regulatory requirements and market needs to the University and the research community, and enable mutual exchange of knowledge by collaborating with researchers and involving students and research fellows. We also aim to work with manufacturers so that they can take the products that have proven their potential to large-scale production in Norway.
Through the network Life Science Pilot, businesses get access to competence beyond what the centre can offer. The network will accelerate product development and be a hotbed for new funding applications nationally and internationally.
Astrid Hilde Myrset
Astrid has a background as PhD in biochemistry (1991) from the University of Oslo and worked in R&D in the Nycomed-Amersham-GE Healhcare business in the period 1994 – 2008 in various roles, including as project manager, knowledge manager and innovation leader. From 2008 to 2012 she was the CEO of the start-up Omegatri AS, and from 2012 to 2017 she was Director for Pre-Clinical and Clinical Research in AlgiPharma AS.
Kristin M. Schoultz
Kristin graduated as a radiochemist with a PhD from the University of Oslo and the University of Duke, Durham, NC in 1999. She worked in Nycomed-Amersham-GE from 1999 to 2010 in various roles, including managing side effects/clinical trials, quality assurance manager in all clinical phases and technology for large scale/commercial development. She was director quality assurance at Clavis Pharma and from 2014 she was department director for biopharmaceutical production at NIPH.
Idunn has a Master degree in toxicology from the University of Oslo (2001) and has worked according to GXP quality systems since 2002. Her experience includes GLP toxicity testing, and quality control for industrial chemicals, pharmaceuticals and medical devices. She has worked at AnalyCen Ecotox and Takeda Nycomed, and been manager for quality control of at the Biopharmaceutical Production at the Norwegian Institute of Public Health.
Gro Helene Osnes
Production and Project Manager
Gro Helene is an officially approved medical technologist, and has a Masters degree in biotechnology from NTNU in 2006. She has analytical experience within cytogenetics, cell differentiation/hematology and blood gas. From 2006, she has worked at Biopharmaceutical Production at the Norwegian Institute of Public Health with contract manufacturing of pharmaceuticals for clinical trials according to GMP and medical devices, as Production and Project manager.
Technical Manager Development
Nikolai is educated electro technician with supplement of chemistry. His experience includes practice as service engineer at equipment suppliers for lab, analysis and chemical processes, and 33 years’ experience at former Nycomed, now GE Healthcare, with development, upscaling and production within organic chemistry. Nikolai is a specialist in development, upscaling and optimalisation of processes.
Hanne C. Grøgaard
Scientist Product Development
Hanne is a Master of science in Biotechnology from NTNU with a thesis in analytical chemistry at Sintef. She has worked with product development, analysis and production within cosmetics, feed and supplement in Aker Biomarine og NutraQ. She has been involved in sales, networking and customer training, and is now working on biological drug process characterization and production development at Diatec.
Microbiologist and QC-analyst
Goro is a Master of Science in Biotechnology with specialization in microbiology, from UMB. She has worked in the food industry as a quality coordinator, where she participated in internal audits and quality work. From 2012 – 2018, she worked according to GMP at the quality control unit at Biopharmaceutical Production at the Norwegian Institute of Public Health, and performed various microbiological analyses.
Yusuf Muhamud Mubiru
Yusuf is educated as a chemist at University of Bergen in 1998 with Master’s degree in Natural Product Chemistry and have previously worked in Polypure and other institutions as a chemist and research assistant, with chemical purification, extraction and analysis. He has been, and still is active in voluntary work in Uganda. Yusuf has a drivers licence for forklift, and works in storage and logistics, besides in process chemistry.
Jhansi is master in Biochemistry from Andhra University in India 2009. She has worked as QA Assistant in Novartis Norway and as lab technician in Invicta, performing chemical analyses. She has also worked as Department Engineer at Biopharmaceutical Production at the Norwegian Institute of Public Health, with responsibility for archiving, environmental control and other GMP related work.
Bjørn Einar has a technology background (ETH Zurich) and has worked the last 15 years in the Venture industry, both in renewable energy and the telecom sector, and has first-hand experience with product development and commercialization in international markets. His previous job was in Hafslund Ventures, and he has therefore been involved in numerous start-up companies as an investor/CEO and/or chairman.
Kjeld-Håkon L. Nilsen
CEO Jandersen Kapital AS
Kjeld-Håkon is a graduate economist and state-authorized public accountant from the Norwegian School of Economics and Business Administration, NHH.
He has 20 years of work experience as an auditor, and has thereby gained knowledge of a number of industries. For the past 10 years in the auditing industry, he ran his own auditing firm, Lani Revisjon AS. As of today, Kjeld-Håkon is a shareholder and general manager of Jandersen Kapital AS, which is a private investment company with extra focus on the life science / biotech industry.
Founder and CEO of Polypure AS
Erik graduated as a peptide chemist with a PhD from the University of Linkoping, and with experience from Nycomed/Amerhsam Health. Through his work, Erik realised the need for pure, high-quality products for pharma and biotech. From 1999 he has established Polypure as a leading provider of monodisperse PEG products for various applications.
Bente Tange Harbø
Sector Manager, IFE Isotope Laboratories
Bente is currently the sector director and heads the Isotope laboratories at IFE. The sector has about 130 employees and accounts for approximately 1/3 of IFE’s sales. Bente is Cand.Pharm from the University of Oslo with a major subject in Galenic Pharmacy and graduated from the ETH Zurich postgraduate program in radio pharmacy. She worked for 11 years in Weifa with tablet formulation and upscaling, and has experience from pharmacy and drug classification / statistics at the NMD / WHO Collaborating Center for Drug Statistics. Since 2001, she has worked at the IFE Isotope laboratories with the development, production and distribution of radioactive drugs. She had a role as QP in the period 2003 to 2013.
Trond is the founder and owner of Kiritec. He is a graduate of Cand. Merc. from Aarhus University, and has 20 years of experience in medical business in Scandinavia. He has primarily worked on the commercialization of niche products within a wide range of specialty areas, and also engages in investment in the biotech / medical sector in Scandinavia and the USA.
General Manager, GE Healthcare AS
Bjørn is Partner at Gevirgroup AS. He has several years of global management experience, with special focus on Norway, US & UK and he has spent his career in the high tech pharmaceutical industry in a variety of management roles, including R&D and discovery & portfolio strategy, Technology Collaboration, Technology Assessment, external communications, global IT as well as real estate & support functions, EHS and indirect sourcing. He is actively working to promote the Life Sciences industry in Norway as a “growing” industry area for a high competence country.
Astrid Hilde Myrset (CEO), Kristin Meret Schoultz (COO), Arne Wang Aabye, Erik Agner – Polypure AS, Bjørn Pedersen – Diatec Monoclonals AS
IFE; Oslotech AS; SINTEF
Inven2 AS; Bergen Teknologioverføring AS; Kjeller Innovasjon AS
Largest private shareholders:
Diatec Monoclonals AS, Myrlid AS, Micro LLC, Jandersen Kapital AS, SurViva AS, Anders Stokvold, IFE Invest, Kiritec AS, André Svee, Pedro Consulting AS, Kristin Merete Schoultz, GE Healthcare AS, Ola Halvorsen, Arne Wang Aabye, Polypure AS, Oslotech AS, Bjørn Fuglaas, Kihl Invest AS, Idunn Sundfør, Olaf Stalsberg, Yusuf Muhammad Mubiru, Bergen Teknologioverføring AS, Audun Myrset Kvalvaag